No insider purchase over the last 90 days. The latest, by Joanne Stent, was filed 02 Apr 2025.
Frontier IP Group plc: what insiders have been doing
Frontier IP Group plc is a Banks company. Its directors and officers file their transactions with RNS (LSE). The past year has been quiet: not a single insider filing for Frontier IP Group plc. The previous disclosure was published on 2 April 2025.
Looking back to 2018, when coverage begins, insiders filed 5 purchases and no sales.
Source: insider filings from RNS (LSE). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -28.4%Entry £0.41 · Close at T+365 £0.29
- +9.0%Entry £0.67 · Close at T+365 £0.73
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended June 2025 · cache
- 0London Stock ExchangeISIN GB00B63PS212RNS:5601567Canonical exit: 1 Jul 2025 (T+90)
- 0London Stock ExchangeISIN GB00B63PS212RNS:5597037Canonical exit: 29 Jun 2025 (T+90)
- 88,000 shares@ £0.405100.0% of flowLondon Stock Exchange (AIM)ISIN GB00B63PS212RNS:4986599-1Canonical exit: 27 Feb 2024 (T+90)
- 250,000 shares@ £0.2688100.0% of flowOutside a trading venueISIN GB00B63PS212RNS:4986599-0
- 62,030 shares@ £0.8960.9% of flowLondon Stock Exchange (AIM)ISIN GB00B63PS212FCA-NSM:4592058Canonical exit: 22 Feb 2023 (T+90)
- 32,932 shares@ £0.65100.0% of flowOutside a Trading Venue - placing of new ordinary sharesISIN GB00B63PS212FCA-NSM:LSE20181121110002_13875562_20200330111438251_10215Canonical exit: 19 Feb 2019 (T+90)
6 of 6 declarations
About Frontier IP Group plc
Frontier IP Group plc is a UK-based company focused on the development and commercialization of innovative technologies. It aims to create partnerships with universities and businesses to transform research into commercial opportunities.
